Journals
The New England Journal of Medicine
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
This week, we will discuss an intriguing hypothesis for many nephrologists: can amino acids prevent acute kidney injury?
This week, we will discuss the blockbuster trial of 2024, FLOW. GLP1RAs have arrived in the nephrology realm.
This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?
This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?
This week, we will discuss Inaxaplin for APOL1 mediated kidney disease (AMKD). Taking the octopus by the horns.
This week, we will discuss the NOSTONE trial. Another renal reversal that will be practice changing. Should we stop using HCTZ for kidney stone prevention.
We love switching from HCTZ or bendroflumethiazide to chlorthalidone or indapamide. We are so smart and smug when we do this. Are we right?
JAMA: Journal of the American Medical Association
This week, we will discuss the BaSICS trial which throws a wrench in the recent dogma regarding the superiority of balanced solutions over normal saline for resuscitation.
Truly a LANDMARK trial. The investigators went to prove that lanthanum is superior to calcium for phosphate binding. What they found will surprise no one.
This week, we will discuss a perspective peice looking at the use of race in the eGFR formulas routinely used in the hospital. #NephJC chat.
First chat of 2019 - showcasing again the honest brokers of nephrology trials with another negative trial. Also note we will be having a NephJC Asia chat starting this week!
This week, we will discuss the use of lanreotide - a somoatostatin analogue, for the treatment of autosomal dominant polycystic kidney disease. An RCT, published in JAMA.
How much water should we drink? Does drinking more water help flush the kidney? Join us as we discuss the definitive trial done to answer this question.
This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!
Join us Dec 19 and 20 as we discuss the MYRE trial from JAMA. Using a high cutoff dialyzer and removing light chains to help the kidneys heal faster
Protocol sepsis management has had a rough few years. Another failure trial, this time from Zambia.
Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?